The second-floor loft on William Street in lower Manhattan, normally abuzz with young equity-options traders connected to Sang Lucci Capital Partners, was quiet for a week last month.
The Sang Lucci crew went to Los Angeles in a quest to find an upgrade for a piece of trading software they say others in the profession have neglected: the human brain.
As part of a study, the traders took a supplement meant to improve cognitive acuteness while buying and selling options and stocks on a simulated platform. All the while a quantitative electroencephalography, or EEG, recorded electrical activity in their brains. A company called TruBrain Inc. ran the tests to see how their pill works on the mind of a trader.
Through its blog and more than 27,000 posts on Twitter, the firm gives outsiders a peek at its trading, and it will soon let researchers examine its trades, said Zhang, who is 26. Robert Battalio, professor of finance at the University of Notre Dame, said in an April 22 phone interview that the data Sang Lucci will provide should help as he examines equity market structure issues.